AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01100489 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: External beam breast radiation therapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.
Study NCT01100489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies: The patient will complete the Cosmesis /QOL form (Appendix II) and the treating physician will complete the Cosmetic Guidelines (skin assessment) form for baseline data (Appendix I).
Study NCT01100489 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patients will undergo excisional biopsy or needle localization removal of the tumor. Patients with margins \< 2 mm undergo re-excision of the biopsy cavity. Surgical clips should be placed at the time of tylectomy to define the excision cavities. Ideally, clips are to be placed marking the superficial, deep, right, left, inferior, and superior dimensions of the tylectomy or re-excision cavities.
Study NCT01445535 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be given with siplizumab and etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin every 21 days
Study NCT01445535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be given with siplizumab and prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
Study NCT01445535 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siplizumab
Description: Siplizumab will be given with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
Study NCT01445535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be given with siplizumab and etoposide, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
Study NCT01445535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be given with siplizumab and etoposide, prednisone, cyclophosphamide, doxorubicin and rituximab every 21 days
Study NCT01445535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given with siplizumab and etoposide, prednisone, vincristine, doxorubicin and rituximab every 21 days
Study NCT01445535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be given with siplizumab and etoposide, prednisone, cyclophosphamide and rituximab every 21 days
Study NCT02718378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estetrol
Study NCT02718378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02264054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]talsaclidine, oral
Study NCT02264054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [14C]talsaclidine, iv
Study NCT02421887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant Supplement
Description: An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine
Study NCT02421887 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00381407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organizational Skills Training
Description: Participants in the OST group attend twenty 1-hour sessions over 10 weeks. OST trains children to use a variety of techniques for improving their organizational skills. Both children and their parents attend every OST session.
Study NCT03087617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual Care for Lung Cancer Screening patients.
Study NCT01896206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CNAP monitor
Description: Patients undergoing bariatric surgery and being monitored using the CNAP monitor.
Study NCT02543749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine
Description: Autologous DC pulsed with leukemia-associated peptides+adjuvant
Study NCT03472170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral administration of bovine lactoferrin (bLf)
Description: The pharmacy service of the hospital will provide the established dose of lactoferrin, according to the regimen of administration of 150 mg / kg / day (maximum 300 mg / day), as well as that of placebo. Both treatments will be administered in liquid form, in the least amount possible. Both the administration of lactoferrin and placebo will be carried out enterally, orally or by nasogastric tube. The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the newborns with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before.
Study NCT03472170 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Enteral administration of placebo
Description: Enteral administration of placebo with similar visual and gustatory characteristics in the first 72 hours of life, and for 4 weeks (6 weeks in the RN ≤ 1000 gr and / or EG ≤ 28 weeks).
Study NCT03828058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus XR
Description: Envarsus XR to be administered orally, once a day. Dosage will be adjusted as determined by trough blood levels.
Study NCT03828058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Prograf 2 mg BID to be administered orally, twice a day. Dosage will be adjusted as determined by trough blood levels.
Study NCT05440539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Handouts
Description: The written materials were generated using the collaboration of healthcare communication specialists to generate content that is tailored to a younger age demographic of childbearing age regarding their risk of developing a pelvic floor disorder and what can be done to prevent or treat them in the future.
Study NCT05440539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Workshop
Description: Participants logged onto a virtual meeting platform and listened to a live 20 minute presentation by a pelvic floor physical therapist followed by time for questions, which were answered live. Participants anonymity was maintained by not allowing participants to view each other's name and disabling sharing of video feeds.
Study NCT01295372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zicronapine
Description: 7.5 mg/day; orally
Study NCT01295372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 5 mg/day; orally
Study NCT00659321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine acid
Description: 16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication
Study NCT00659321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 16 weeks treatment with placebo
Study NCT01720264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.
Study NCT04699149 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Non-invasive brain stimulation
Study NCT04699149 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial magnetic stimulation
Description: Non-invasive brain stimulation
Study NCT04332861 — intervention group
Intervention type: OTHER
Intervention: Initial clinical and laboratory evaluation
Description: Initial evaluation, prior to administration of any antibiotics if possible, includes history, physical exam, and labs including:~* Urinalysis~* Urine culture~* Blood cultures~* Complete blood count with differential~* Comprehensive metabolic panel~* Lactate~* Procalcitonin~* Other inflammatory markers
Study NCT00006409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trial of Activity for Adolescent Girls (TAAG)
Description: Intervention activities were designed to create (1) environmental and organizational changes supportive of physical activity and (2) cues, messages, and incentives to be more active. The intervention was designed to establish more opportunities, improve social support and norms, and increase self-efficacy, outcome expectations, and behavioral skills to foster greater moderate-vigorous physical activity (MVPA). An innovative feature of TAAG was linking school and community agencies to promote activity programs for girls. Finally, a TAAG Program Champion component was developed to foster sustainability after the 2-year staff-directed intervention. TAAG investigators recruited and trained Program Champions during the staff-directed intervention phase to promote maintenance of the program.
Study NCT00390013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: 300 mg. capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~1. day 1 you will take 1 capsule for the day~2. day 2 you will take 1 capsule 2 times for that day~3. days 3-6 you will take 1 capsule 3 times for those days~4. days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~5. days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~6. days 13-14 you will take 2 capsules 3 times each day~7. continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~8. at completion of study treatment you will titrate off study drug over a weeks time.
Study NCT00390013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~1. day 1 you will take 1 capsule for the day~2. day 2 you will take 1 capsule 2 times for that day~3. days 3-6 you will take 1 capsule 3 times for those days~4. days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~5. days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~6. days 13-14 you will take 2 capsules 3 times each day~7. continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~8. at completion of study treatment you will titrate off study drug over a weeks time.
Study NCT02993367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylphthalide Soft Capsules
Description: DL-3-n-butylphthalide (NBP) (Fig. 1) is a synthetic chiral compound containing L- and D-isomers of butylphthalide.Butylphthalide Soft Capsules is the oral preparation.
Study NCT02993367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Butylphthalide Soft Capsules
Study NCT03048526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaTears®
Description: Topical eye drops for lubrication of the ocular surface
Study NCT03048526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrabak®
Description: Eye drops
Study NCT02164448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the dexmedetomidine group
Description: the dexmedetomidine group: dexmedetomidine infusion from induction of anesthesia to end of surgery
Study NCT02164448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: the control group
Description: saline infusion from induction of anesthesia to end of surgery
Study NCT03401996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 mA tDCS over bilateral SMA
Description: A 1mA direct current will be delivered through two 5cm x 5cm saline-soaked surface sponge electrodes by a battery-driven, constant-current stimulator (Neuroconn DC stimulator). First, the SMA will be identified based on the guidelines of the international 10-20 electrode system. The tDCS will then be applied using the following procedure:~1. The head of participants will be measured to find the 'vertex' (top) of the head. This point will be used as a landmark to locate the SMA. This region corresponds to the FCZ (e.g., Legon et al., 2013).~2. The return electrode will be placed over the mastoids. Once the electrodes are in position, cathodal tDCS will be applied at 1mA for 15 minutes, 2 times a day with a resting period of 20 minutes in between treatment periods, for 5 consecutive days.
Study NCT03401996 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 1 mA tDCS over bilateral SMA
Description: A 1mA direct current will be delivered through two 5cm x 5cm saline-soaked surface sponge electrodes by a battery-driven, constant-current stimulator (Neuroconn DC stimulator). First, the SMA will be identified based on the guidelines of the international 10-20 electrode system. The tDCS will then be applied using the following procedure:~1. The head of participants will be measured to find the 'vertex' (top) of the head. This point will be used as a landmark to locate the SMA. This region corresponds to the FCZ (e.g., Legon et al., 2013).~2. The return electrode will be placed over the mastoids. Once the electrodes are in position, cathodal tDCS will be applied at 1mA for 15 minutes, 2 times a day with a resting period of 20 minutes in between treatment periods, for 5 consecutive days.
Study NCT01471093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-12759 Ophthalmic solution
Description: 2％ OPC-12759 Ophthalmic solution
Study NCT01471093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPC-12759 Ophthalmic suspension
Description: 2％ OPC-12759 Ophthalmic suspension
Study NCT01974648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Study NCT00888745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous and subcutaneous ascending dose
Study NCT00888745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO283698
Description: Intravenous and subcutaneous ascending dose
Study NCT01246284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: Injections will be given within a 3 cm2 area of alopecia which will be divided into 4 quadrants. Three different concentrations of triamcinolone acetonide will be used: 2.5, 5, and 10 mg/ml. Each quadrant will receive injections with either triamcinolone acetonide 2.5 mg/ml, triamcinolone acetonide 5 mg/ml, triamcinolone acetonide 10 mg/ml, or normal saline as a control. Injection of 0.1 ml will be given intradermally using a 30 gauge half inch long needle attached to a 3 ml syringe. Each quadrant will receive approximately 7 injections per treatment session so the total dose of triamcinolone acetonide will be around 13 mg. Injections will be given vertically, with the beveled side of the needle directed to the opposite side and 2 mm away from the margin of the adjacent quadrant to avoid a diffusion effect. The treatment will be repeated every 4 to 6 weeks for a total of 6 treatment sessions.
Study NCT01974648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol and remifentanil
Study NCT03142360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (Berasil)
Description: Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
Study NCT01965522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin 20mg taken orally once daily. This is in the form of one capsule which contains two pills of melatonin, 10 mg each.
Study NCT01965522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 2000 IU taken orally once daily. This is in the form of one capsule which contains two pills of vitamin D, 1000 IU each.
Study NCT01965522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (melatonin)
Description: Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains melatonin tablets.
Study NCT01965522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (melatonin)
Description: Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains melatonin tablets.
Study NCT01965522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (vitamin D)
Description: Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains vitamin D tablets.
Study NCT01965522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vitamin D)
Description: Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains vitamin D tablets.
Study NCT03916497 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantiferon CMV
Description: Evaluate and compare interferon gamma (IFNy) production by T CD8 cells exposed to CMV antigens in CMV seropositive kidney transplant recipients, hemodialysis and control patients
Study NCT01246284 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study NCT01211249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0259 oral capsule
Description: Two capsules, each containing 25 mg of GLPG0259 (i.e. 50 mg/day), to be given once daily; in case of adverse events the dose may be split over two administrations, or reduced to 25 mg/day (one single capsule)
Study NCT00614952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PSG (polysomnography)
Description: POLYSOMNOGRAPHY
Study NCT00614952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PR (respiratory polygraphy)
Description: respiratory polygraphy: level III of AASM
Study NCT01159132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: 12 hour PK will be done on day 1 while subjects is on stable regimen with RAL 400 mg BID. After performing intensive PK, subjects will be randomized to either group A (RAL 400 mg OD) or B (RAL 800 mg OD) for 14 days and on day 15, a second 24 hour full PK will be carried out. After the intensive PK, subjects in both the groups will switched to the other dosing regimen, group A (RAL 800 mg OD) and B (RAL 400 mg OD) for another 14 days and on day 29, the third 24 hour full PK will be carried out.
Study NCT02461771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: On treatment day, subjects will be administered a single 100 μL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment.
Study NCT01763385 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Erlotinib
Study NCT01763385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study NCT01763385 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: concurrent brain radiotherapy
Study NCT01763385 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: secondary brain radiotherapy
Study NCT04058288 — intervention group
Intervention type: DEVICE
Intervention: High-definition Transcranial Direct Current Stimulation
Description: Stimulation sessions will be conducted on 2 different visits separated by 2-week gap. In a crossover design, Anodal HD-tDCS will be delivered either in Active/Sham mode (during the first visit) and Sham/Active during the second visit in a 4x1 ring configuration (center electrode being Anode and the surrounding 4 electrodes being cathodes) over the affected motor area.
Study NCT01661686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Partially covered SEMS
Description: Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available
Study NCT01661686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fully covered SEMS
Description: Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available
Study NCT04645615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardioblate surgical ablation system
Description: This investigation is a prospective, non-randomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
Study NCT04645615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical RF Ablation
Description: This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
Study NCT03649841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiandrogen Therapy
Description: Undergo ADT
Study NCT03649841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Undergo ADT
Study NCT03649841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: Undergo Abiraterone Acetate Treatment SOC
Study NCT03649841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Undergo Abiraterone Acetate Treatment SOC
Study NCT03649841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Undergo Prednisone Treatment SOC
Study NCT03649841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Undergo Prednisone Treatment SOC